Efficacy, safety profile, and immunogenicity of alglucosidase alfa produced at the 4,000-liter scale in US children and adolescents with Pompe disease: ADVANCE, a phase IV, open-label, prospective study Response
Volume
20
Pagination
1295 - 1295
DOI
10.1038/gim.2017.256
Journal
GENETICS IN MEDICINE
Issue
ISSN
1098-3600